Methylene Blue & Electron Transport Chain — References

Mirrored Reference Dossier

Parent Topic: Methylene Blue & Electron Transport Chain | References Hub: 02 - Compounds & Molecules References MOC

---

Landmark Peer-Reviewed Studies

1. Rojas, Bruchey, & Gonzalez-Lima (2012) — Progress in Neurobiology

• Citation: Rojas, J. C., Bruchey, A. K., & Gonzalez-Lima, F. (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology, 96(1), 32–45.
• Identifiers: PMID: 22067440 (PubMed · Europe PMC) | PMCID: PMC3265679 (PMC Full Text) | DOI: 10.1016/j.pneurobio.2011.10.007 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Comprehensive biochemical, histochemical, and neurobehavioral synthesis of Methylene Blue’s electron transport chain redox cycling and hormetic dose-response pharmacology.
• Key Quantitative Outcomes: Established that low-dose Methylene Blue ($0.5\text{–}4.0\text{ mg/kg}$) acts as a catalytic electron cycler ($E_0^{\prime }=+11\text{ mV}$) between mitochondrial NADH dehydrogenase (Complex I) and Cytochrome c (Complex IV), increasing cerebral Cytochrome c Oxidase (Complex IV) enzymatic activity by $+25\text{–}30\%$ ($p<0.01$), boosting cerebral oxygen consumption by $+37\text{–}70\%$, preventing rotenone-induced Complex I neurodegeneration, and enhancing 24-hour memory retention across spatial, object-recognition, and fear-extinction tasks. Detailed the biphasic hormetic ceiling where doses $\ge 10\text{ mg/kg}$ reverse electron flow and lose procognitive efficacy.

2. Rodriguez et al. (2016) — Radiology

• Citation: Rodriguez, P., Zhou, W., Barrett, D. W., Altmeyer, W., Fox, P. T., Lancaster, J. L., Gonzalez-Lima, F., & Duong, T. Q. (2016). Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology, 281(2), 516–526.
• Identifiers: PMID: 27351678 (PubMed · Europe PMC) | PMCID: PMC5084348 (PMC Full Text) | DOI: 10.1148/radiol.2016152893 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Randomized, double-blind, placebo-controlled functional MRI (fMRI) and arterial spin labeling (ASL) trial in healthy human adults aged 22–62 years ($N=26$) evaluating a single low oral dose of USP Methylene Blue ($280\text{ mg}$, or $\sim 0.5\text{–}4.0\text{ mg/kg}$ range).
• Key Quantitative Outcomes: Methylene Blue significantly increased task-evoked fMRI activation in the bilateral insular cortex during sustained psychomotor vigilance ($p=0.01\text{–}0.008$) and significantly increased fMRI activation in the prefrontal, parietal, and occipital cortices during delayed match-to-sample visuospatial working memory encoding and retrieval ($p<0.01$), accompanied by a $+7.0\%$ increase in correct memory retrieval responses ($p=0.01$).

3. Xiong et al. (2017) — Scientific Reports (Nature Portfolio)

• Citation: Xiong, Z. M., O’Donovan, M., Sun, L., Choi, J. Y., Ren, M., & Cao, K. (2017). Anti-aging potentials of methylene blue for human skin longevity. Scientific Reports, 7(1), 2475.
• Identifiers: PMID: 28559565 (PubMed · Europe PMC) | PMCID: PMC5449383 (PMC Full Text) | DOI: 10.1038/s41598-017-02419-3 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Comparative mitochondrial ROS and cellular senescence study in normal human dermal fibroblasts (from young, $80\text{-year-old}$, and Hutchinson-Gilford progeria donors) and 3D organotypic human skin tissue comparing Methylene Blue ($100\text{ nM}$) against NAC, MitoQ, and MitoTEMPO.
• Key Quantitative Outcomes: Methylene Blue was the most effective antioxidant tested, scavenging mitochondrial superoxide, upregulating Nrf2 expression by $+2\text{-fold}$, increasing Type I ($\text{COL1A1}$) and Type III ($\text{COL3A1}$) collagen and elastin mRNA by $+2\text{- to }3\text{-fold}$ ($p<0.01$), extending fibroblast replicative lifespan by $>20$ population doublings, and increasing 3D human epidermal dermis thickness and hydration while accelerating wound closure.

4. Ramsay et al. (2007) — British Journal of Pharmacology

• Citation: Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007). Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology, 152(6), 946–951.
• Identifiers: PMID: 17721552 (PubMed · Europe PMC) | PMCID: PMC2078225 (PMC Full Text) | DOI: 10.1038/sj.bjp.0707430 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Recombinant human Monoamine Oxidase A (MAO-A) and Monoamine Oxidase B (MAO-B) spectrophotometric enzyme kinetics and fluorescence binding study.
• Key Quantitative Outcomes: Proved that Methylene Blue is an exceptionally potent, tight-binding reversible competitive inhibitor of human Monoamine Oxidase A (MAO-A) with a $K_i=27\pm 3\text{ nM}$ and ${\text{IC}}_{50}=164\pm 8\text{ nM}$ (while inhibiting MAO-B only weakly at ${\text{IC}}_{50}=5.5\mu \text{M}$)—confirming that plasma and CNS concentrations achieved even at low oral doses ($0.5\text{–}2.0\text{ mg/kg}$) substantially inhibit MAO-A and explaining the strict contraindication with SSRI/SNRI medications.